|
Tools & Techniques to Enhance Surgical Efficacy & Efficiency
This series of six webcasts offers insight on various issues that are important to eye care professionals. Each of the webcasts features individualized content, including how to run an efficient practice while caring for patients in the COVID-19 era; use of high-quality screening, monitoring and imaging devices across eye care subspecialties; thorough discussions on why connectivity and transfer of preoperative data to intraoperative technology is necessary for optimal visual outcomes; and the... |
|
Tools & Techniques to Enhance Surgical Efficacy & Efficiency
This series of six webcasts offers insight on various issues that are important to eye care professionals. Each of the webcasts features individualized content, including how to run an efficient practice while caring for patients in the COVID-19 era; use of high-quality screening, monitoring and imaging devices across eye care subspecialties; thorough discussions on why connectivity and transfer of preoperative data to intraoperative technology is necessary for optimal visual outcomes; and the... |
|
Chronic Versus Acute: Rethinking Dry Eye Disease
This continuing education activity (CE) captures content from a virtual roundtable discussion.
ACTIVITY DESCRIPTION
Dry eye disease (DED) is a significant public health issue that threatens patient economic productivity and quality of life. About 16 million Americans have a formal DED diagnosis, but the true incidence is likely much higher because many who are symptomatic may not seek medical care. This supplement addresses this issue and others related to managing DED and providing the ... |
|
Neuromyelitis Optica Spectrum Disorder: Management Updates and Challenging Clinical Cases
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease of the central nervous system that mainly manifests through recurrent attacks of optic neuritis and longitudinally extensive transverse myelitis. NMOSD is often misdiagnosed in the early stages, but the integration of newer diagnostic criteria may assist in an earlier and more accurate differential diagnosis. Until recently, treatment options for NMOSD have been limited―but several approved biologic thera... |
|
Neuromyelitis Optica Spectrum Disorder: Management Updates and Challenging Clinical Cases
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease of the central nervous system that mainly manifests through recurrent attacks of optic neuritis and longitudinally extensive transverse myelitis. NMOSD is often misdiagnosed in the early stages, but the integration of newer diagnostic criteria may assist in an earlier and more accurate differential diagnosis. Until recently, treatment options for NMOSD have been limited―but several approved biologic thera... |
|
Ocular Surface Health and Surgical Outcomes
Nearly 33% of patients in eye care clinics present with complaints about dry eye signs and symptoms. Clinicians remain challenged with both the diagnosis and best treatment options for dry eye disease (DED) because, to date, multiple causes of the disorder have been identified. This activity will help to inform clinicians on methods to improve the care of patients with DED. |
|
OSD: Improving Patient Outcomes Through Collaborative Care
Nearly 33% of patients in eye care clinics present with complaints about dry eye signs and symptoms. Clinicians remain challenged with both the diagnosis and best treatment options for dry eye disease (DED) because, to date, multiple causes of the disorder have been identified. This activity will help to inform clinicians on methods to improve the care of patients with DED. |
|
Tracking and Treating Uveitic Macular Edema: A Difficult Dilemma
Uveitic macular edema (UME) has a wide variety of causes. If not appropriately treated, it eventually causes damage to the photoreceptors in the macula, resulting in vision-threatening complications like macular ischemia or macular hole formation. Corticosteroids are the first-line treatment for uveitic inflammation and UME. However, they are not generally considered to be appropriate for long-term treatment due to adverse effects, including increased intraocular pressure and cataract in local... |
|
Tracking and Treating Uveitic Macular Edema: A Difficult Dilemma
Uveitic macular edema (UME) has a wide variety of causes. If not appropriately treated, it eventually causes damage to the photoreceptors in the macula, resulting in vision-threatening complications like macular ischemia or macular hole formation. Corticosteroids are the first-line treatment for uveitic inflammation and UME. However, they are not generally considered to be appropriate for long-term treatment due to adverse effects, including increased intraocular pressure and cataract in local... |
|
Diabetic Macular Edema: Employing Inflammatory Markers to Predict Improved Visual Outcomes
Real-world outcomes with intravitreal anti-vascular endothelial growth factor (VEGF) therapy in the treatment of patients with diabetic macular edema (DME) do not always replicate those seen in clinical studies. In part, these discrepancies are due to treatment burden, lack of adherence, undertreatment, and incomplete response to anti-VEGF therapies. The identification of several inflammatory cytokines in the aqueous and vitreous humor whose concentrations correlate closely with the severity o... |
|
Diabetic Macular Edema: Employing Inflammatory Markers to Predict Improved Visual Outcomes
Real-world outcomes with intravitreal anti-vascular endothelial growth factor (VEGF) therapy in the treatment of patients with diabetic macular edema (DME) do not always replicate those seen in clinical studies. In part, these discrepancies are due to treatment burden, lack of adherence, undertreatment, and incomplete response to anti-VEGF therapies. The identification of several inflammatory cytokines in the aqueous and vitreous humor whose concentrations correlate closely with the severity o... |
|
nAMD and DME Management: Rapid Response From ARVO
Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing... |
|
nAMD and DME Management: Rapid Response From ARVO
Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing... |
|
Geographic Atrophy: Rapid Response from ARVO
Geographic atrophy (GA) is a pathological deterioration of the retina seen in the late stages of age-related macular degeneration (AMD). It affects 20% of people with AMD, and its prevalence increases exponentially with age. Until recently, there were no treatment options for GA, but investigation into the complement system and its role in the pathogenesis of GA has led to targeted therapies that have revolutionized the treatment paradigm. Because of the recent approval of one of these therapi... |
|
A Class Act in Glaucoma Management: Differentiating Rho Kinase Inhibitors From the Pack
Medical management of glaucoma primarily focuses on lowering intraocular pressure (IOP) by decreasing aqueous production, reducing episcleral venous pressure, and/or increasing uveoscleral and trabecular outflow. Recently approved agents have expanded treatment options beyond the traditional mainstays of prostaglandin analogues and β-blockers, engaging Rho kinase (ROCK) inhibition to improve outcomes for patients with glaucoma. In this CE monograph, experts in the field will review the clinic... |
|
Eyeing the Options for Treating Meibomian Gland Dysfunction and Dry Eye Disease
Dry eye disease (DED) is highly prevalent but frequently underdiagnosed and subsequently undertreated. Studies have demonstrated that meibomian gland dysfunction (MGD) is a leading cause of the development and progression of evaporative DED, caused by a deficient tear film lipid layer that leads to increased tear evaporation. New and emerging treatments with novel mechanisms of action are being investigated that manage the signs and symptoms of DED associated with MGD and offer the potential f... |
|
Case Challenges in nAMD and DME Management: Achieving Durable Response
The management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with intravitreal anti-vascular endothelial growth factor (VEGF) therapies has provided enhanced visual outcomes for many patients. However, the high treatment burden associated with anti-VEGF therapies can lead to lack of patient adherence, resulting in suboptimal outcomes. Personalized treatment protocols using FDA-approved agents and newer novel delivery systems, along with agents with uni... |
|
Meeting Milestones in nAMD and DME Management: What's New?
Anti-vascular endothelial growth factor (VEGF) therapy has revolutionized treatment paradigms for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, these agents are associated with a high treatment burden because of the injection frequency, and a substantial number of patients do not adhere to their treatment schedules, resulting in suboptimal response to therapy. To address these issues, new dosage regimens and surgical drug delivery approaches hav... |
|
Ace the Case: An 84-Year-Old Man With Neovascular Age-Related Macular Degeneration Receiving Bilateral Every 8-Week Anti-Vascular Endothelial Growth Factor Injections
In this clinical case review, Dr. Emmanuel Chang explores options to extend treatment intervals in a patient with stable nAMD who is receiving anti-VEGF therapy every 8 weeks. |
|
Ace the Case: A 65-Year-Old Woman With Chronic Diabetic Macular Edema in Both Eyes
In this clinical case review, Dr. Sara Haug explores considerations for the management of a patient with DME who is receiving monthly anti-VEGF therapy without attaining disease control. |
|
Ace the Case: A 76-Year-Old Male With Active Neovascular Age-Related Macular Degeneration
In this clinical case review, Dr. Arshad Khanani explores options for switching treatment in a patient with nAMD who has become nonresponsive to anti-vascular endothelial growth factor (VEGF) therapy. |
|
Secrets of Egypt & the Nile: Joint Medical/Dental Symposium Confronting Healthcare Needs
Uncover Egypt’s ancient secrets with PES for 11 nights on this bucket list adventure! Visit iconic landmarks, temples, and monuments and cruise the Nile in a manner once reserved for pharaohs aboard the luxurious, 72-guest AmaDahlia.
Joint Medical/Dental Symposium Confronting Healthcare Needs
CME/CE Lecture Seminars for Medical, Dental, Nursing, and Allied Healthcare Professionals
This Seminar is planned for 14 Continuing Education Credit Hours.
CME/CE Professional Seminar Fee:... |
|
Recognition and Referral: Best Practices for Managing Patients with GA
Patients with advanced dry age-related macular degeneration can present with geographic atrophy (GA), a disease that is progressive and increases with age. Although there is no treatment approved by the FDA that halts or reverses GA, a number of drugs in the pipeline are designed to address GA progression, hoping to succeed where previous drug candidates failed. This series of regional, interactive, virtual symposia are designed to educate eye care providers on the importance of diagnosis and ... |
|
Putting Patients First: Best Practices for Neurotrophic Keratitis Diagnosis and Treatment
This previously recorded satellite symposium features an engaging presentation on the potential causes of neurotrophic keratitis, how to differentiate it from similar diseases, and when referrals may be necessary. Treatment options will also be discussed, including the mechanisms of action of newer therapies and when they should be introduced.
Case discussions and audience question-and-answer session were also recorded. |
|
Individualizing Glaucoma Treatment: Understanding How to Utilize Traditional and Novel Agents
Join Nathan M. Radcliffe, MD, and Justin Schweitzer, OD, FAAO, as they discuss the ways in which novel therapeutics may help to overcome the challenges and limitations associated with currently available pharmacologic treatment options for ocular hypertension and primary open-angle glaucoma. |
|
Neurotrophic Keratitis: Old Problem, New Solutions
Eye care providers may not understand what neurotrophic keratitis is or how it differs from other corneal diseases. In addition; eye care practitioners may be unaware of treatments in development, or the already approved treatments for neurotrophic keratitis. They also may not understand the mechanism of action of these newer treatments. |